HeartBeam acquires patient monitoring assets from Livmor
HeartBeam (Nasdaq:BEAT) announced today that it acquired substantially all assets from Livmor, which develops remote monitoring technology.
Related Articles
GenAI company Alaffia Health raises $10M and more digital health
Pediatric chronic care company Clarity Pediatrics also secured $10 million in seed funding and Los Angeles-based Handl Health brought in $2.5M.
LunaJoy nabs $4.2M to roll out integrated maternal mental health program with partners
LunaJoy Health, a women-focused mental health provider, has raised $4.2 million in funding and announced the launch of its integrated care program, LunaCare. | Drawing…
Blue Arbor wins FDA breakthrough nod for neuromuscular interface
Blue Arbor Technologies announced today that it received FDA breakthrough device designation for its Restore neuromuscular interface system.
Summer Health pockets $12M series A to grow text-based pediatric service
Summer Health, a pediatric telehealth messaging service launched just 18 months ago, picked up $11.65 million in series A funding to build out its technology…
FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery – MedCity News
ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The novel immunotherapy works by sparking activity from three types…
Dexcom, Abbott benefit from non-insulin, basal CGM user increase
William Blair analyst Margaret Kaczor reported surprise at the increase in users of CGM within the non-insulin and basal insulin populations.
There’s a big market for healthcare data analytics. Here’s how Trilliant Health is making moves to stand out
The $4 trillion healthcare industry is a data-rich sector, and every healthcare player is trying to find a way to use information to drive better…
Cohere Health expands partnership with Humana
The health insurance company will expand its use of Cohere’s prior authorization platform to include diagnostic imaging and sleep services.
EU launches probe of China’s medical device market
China’s procurement market for medical devices has gradually become more closed for European and foreign companies, the European Commission alleges.
AI-enabled drug discovery company Xaira launches with $1B
Xaira’s CEO, Dr. Marc Tessier-Lavigne, resigned as president of Stanford University last August due to controversy over inaccuracies discovered in his lab’s scientific papers.